Craig L. Slingluff, MD [clinicaltrials_resource:d60ec7a70aa912e5d71211f09aae527a]
clinicaltrials:NCT00003222clinicaltrials:NCT00003224clinicaltrials:NCT00071981Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00089193]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [clinicaltrials:NCT00089206]clinicaltrials:NCT00089219
overall official [clinicaltrials_vocabulary:overall-official]
Craig L. Slingluff, MD [clinicaltrials_resource:d60ec7a70aa912e5d71211f09aae527a]
Bio2RDF identifier
d60ec7a70aa912e5d71211f09aae527a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d60ec7a70aa912e5d71211f09aae527a
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
CLS8H@hscmail.mcc.virginia.edu
cls8h@virginia.edu
last name [clinicaltrials_vocabulary:last-name]
Craig L. Slingluff, MD
phone [clinicaltrials_vocabulary:phone]
434-924-1730
617-632-3012
role [clinicaltrials_vocabulary:role]
Study Chair
identifier
clinicaltrials_resource:d60ec7a70aa912e5d71211f09aae527a
title
Craig L. Slingluff, MD
@en
type
label
Craig L. Slingluff, MD [clinicaltrials_resource:d60ec7a70aa912e5d71211f09aae527a]
@en